Elsevier

Journal of Cystic Fibrosis

Volume 11, Issue 6, December 2012, Pages 461-479
Journal of Cystic Fibrosis

Review
Treatment of lung infection in patients with cystic fibrosis: Current and future strategies,☆☆

https://doi.org/10.1016/j.jcf.2012.10.004Get rights and content
Under an Elsevier user license
open archive

Abstract

In patients with cystic fibrosis (CF) lung damage secondary to chronic infection is the main cause of death. Treatment of lung disease to reduce the impact of infection, inflammation and subsequent lung injury is therefore of major importance. Here we discuss the present status of antibiotic therapy for the major pathogens in CF airways, including prophylaxis against infection, eradication of early infection, suppression of chronic infection, and the treatment of infective exacerbations. We outline measures to optimize maintenance treatment for infection in the light of novel antibiotic drug formulations. We discuss new developments in culture-independent microbiological diagnostic techniques and the use of tools for monitoring the success of antibiotic treatment courses. Finally, cost-effectiveness analyses for antibiotic treatment in CF patients are discussed.

Cited by (0)

This document is the result of a European Consensus Conference which took place in Artimino, Tuscany, Italy, on April 27–29, 2012, involving various international experts on antibiotic therapy against microbial pathogens in cystic fibrosis patients, organized by the European Cystic Fibrosis Society, and sponsored by Aptalis, Bayer Schering Pharma, Chiesi, Forest Laboratories UK Ltd, Gilead Sciences, Inc., Insmed Incorporated, Novartis Pharma and Pari Pharma GmbH. The purpose of the conference was to develop a consensus document on current and future strategies for the treatment of lung disease in cystic fibrosis based on current evidence.

☆☆

Disclaimer. The views presented in this Correspondence are those of the authors and should not be understood or quoted as being made on behalf of the European Medicines Agency or its scientific Committees.